Replies to post #151555 on Biotech Values

[genisi]

Copaxone is still holding more than 40% of MS drugs market share.

[DewDiligence]

4Q12 US Copaxone sales were $822M (an annualized rate of $3.3B), +11% YoY and +6% QoQ:

http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=1782674&highlight=